Cross-protective immunity against o鈥榥yong-nyong virus afforded by a novel recombinant chikungunya vaccine

详细信息	查看全文 | 推荐本文 |

• 作者：Charalambos D. Partidos^a ; ^{hpartidos@inviragen.com} ; Joanna Paykel^a ; James Weger^b ; Erin M. Borland^c ; Ann M. Powers^c ; Robert Seymour^d ; Scott C. Weaver^d ; Dan T. Stinchcomb^e ; Jorge E. Osorio^a ; ^b
• 关键词：Chikungunya virus (CHIKV) ; O&lsquo ; nyong&ndash ; nyong virus (ONNV) ; A129 mice ; Interferon (IFN) ; Maternal&ndash ; fetal immunity
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：29 June, 2012
• 卷：30
• 期：31
• 页码：4638-4643
• 文件大小：728 K

摘要

Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o鈥榥yong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.